Taletrectinib companion diagnostics - AnHeart Therapeutics/Guardant Health
Alternative Names: Taletrectinib Guardant360 TissueNext™ companion diagnostics - AnHeart Therapeutics/Guardant Health; Taletrectinib Guardant360® CDx companion diagnostics - AnHeart Therapeutics/Guardant HealthLatest Information Update: 17 Apr 2024
Price :
$50 *
At a glance
- Originator Guardant Health
- Developer AnHeart Therapeutics; Guardant Health
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Non-small cell lung cancer
Most Recent Events
- 10 Apr 2024 AnHeart Therapeutics has been acquired by Nuvation Bio
- 02 Feb 2023 Guardant Health and AnHeart Therapeutics enters a collaboration to develop Guardant360® CDx and Guardant360 TissueNext™ as companion diagnostics for taletrectinib in Non-small cell lung cancer
- 02 Feb 2023 Early research in Non-small cell lung cancer (Diagnosis) in USA (unspecified route)